Infectious complications were retrospectively analyzed in 129 transplants, performed in 90 patients, to identify characteristics that qualify breast cancer patients for outpatient-based PBSCT. Thirty-one cases (24%) did not develop fever. Of the remaining 98 cases, 84.7% developed fever during severe neutropenia. On univariate analysis, disease stages II-III, first PBSCT, mucositis grades II-IV and the use of two alkylators were associated with a higher risk of fever development. The latter two factors also affected fever occurrence on multivariate analysis. A longer median time to fever onset was observed in patients conditioned with single as compared to double alkylating agent-containing regimens (respectively 8th vs 6th day, P Ͻ 0.00001). As compared with metastatic breast cancer (MBC), high risk breast cancer showed a 2.3-fold increased risk of developing early fever during neutropenia (CI 2.3-3.8), remaining the only variable still significant on multivariate analysis (P = 0.0039). Combination antibiotic therapy was equivalent to single agent therapy. Patients suffering from microbiologically documented fever were at higher risk of undergoing second-line antibiotic therapy. In conclusion, MBC patients treated with a conditioning regimen containing only one alkylating agent and adequate prophylaxis for mucositis may qualify for outpatientbased PBSCT on the basis of a lower risk of infection. Bone Marrow Transplantation (2001) 28, 883-888. Keywords: breast cancer; stem cell transplant; infection; outpatient High-dose chemotherapy (HDC) followed by peripheral blood stem cell transplantation (PBSCT) is increasingly being used
in the treatment of breast cancer (BC) patients. [1] [2] [3] [4] Although this procedure produces a high response rate in metastatic (M) BC, 1, 2 whether PBSCT improves overall survival in both MBC and high risk (HR) BC is still open to question. 5, 6 The major cause of morbidity and mortality in patients undergoing HDC and stem cell support is infection, due to a variety of factors such as skin damage, central venous catheter (CVC) insertion and, most importantly, granulocytopenia. 7, 8 Considering that the severity of infection depends on the degree and duration of myelosuppression, both the infusion of peripheral stem cells and the administration of granulocyte colony-stimulating (G-CSF) factor are used to accelerate neutrophil recovery, thus reducing the rate of infectious complications. 9, 10 In addition, antimicrobial prophylactic regimens have been demonstrated to be effective in the prevention of infections in transplant patients. 11, 12 Recently, there have been considerable concerns regarding appropriate use of health care resources in order to reduce costs associated with PBSCT. Outpatient-based PBSCT is one of the strategies attempted to reach this goal and this may be possible by reducing complications that necessitate hospitalization. 13 In this report, we retrospectively analyzed infectious complications during neutropenia subsequent to HDC in both metastatic and HRBC patients who all received PBSCT autografting, antimicrobial and antiviral prophylaxis, and G-CSF post transplant. The final aim was to collect adequate information for a prospective design of outpatient-based, rather than traditional inpatient-based, PBSCT in BC patients.
Patients and methods

Protocols, patient characteristics and HDC
Between July 1995 and January 2000, 90 BC patients entered four different PBSCT protocols: (1) two Gruppo Oncologico Calabrese (GOCAM) studies for MBC, con-sisting of induction chemotherapy with epirubicin 120 mg/m 2 and cyclophosphamide 600 mg/m 2 × 3 cycles followed by a double HDC (first HDC consisting of cyclophosphamide, thiotepa and carboplatinin in GOCAM-RC01 and melphalan and thiotepa in GOCAM-RC02, while the second HDC was mitoxantrone and melphalan for both protocols) and PBSCT; 3, 4 (2) a European Union sponsored study for resistant MBC, consisting of mobilization therapy with taxotere 100 mg/m 2 followed by a triple PBCT program, the first HDC with melphalan, the second with thiotepa and the third with melphalan; (3) high-dose sequential chemotherapy with a conditioning regimen consisting of mitoxantrone and melphalan with PBSCT, as previously published by the Milan group; 14 and (4) ) with a single HDC (thiotepa and melphalan). 15 All HRBC patients underwent a single transplant, and a single alkylating regimen was administered in only one patient. Of the 109 transplants performed in MBC, a single alkylator was administered in 56; in terms of MRC patients undergoing transplantation, 53 out of 70 patients received more than one alkylator. A CVC was implanted before hospitalization. A total of 129 PBSCT were evaluated. Patient characteristics are shown in Table 1 . Conditioning regimens, the doses of which are described in Table 1 , may be ultimately subdivided into two groups according to the number of alkylators used; a single alkylating agent-containing regimen was administered in 57 cases, while more than one alkylator was administered in 72 cases. The median number of CD34
+ cells infused was 6 × 10 6 /kg. ANC Ͼ100/l 6.7 ± 2.1 ANC Ͼ500/l 8.4 ± 1.9 ANC Ͼ1000/l 9.1 ± 2.0 Interval PBSC infusion-discharge (mean days ± s.d.)
13.0 ± 5.6
Prophylaxis
During the aplastic phase, all patients were admitted to a positive-pressure reverse isolation room. All patients received prophylaxis including oral ciprofloxacin (500 mg every 12 h), acyclovir (800 mg every 8 h), either fluconazole (300 mg/day) or itraconazole (200 mg/day) orally from day −5 until neutrophil recovery and trimethoprim/ sulphometaxazole from day −8 to day 0. All patients received G-CSF at a dose of 5 g/kg/day starting from 72 h after stem cell infusion until the neutrophil count was above 1.0 × 10 9 /l for 3 consecutive days; the first day was accepted as the day of neutrophil engraftment.
Microbiological investigations and antimicrobial therapy
Clinical examinations were performed once daily and body temperature was measured at least three times a day. A febrile episode was defined as an axillary temperature exceeding Ͼ38°C in at least two consecutive episodes, in the absence of an obvious non-infectious cause of fever, such as transfusion of blood products, administration of cytotoxic drugs or cancer-related fever. Infectious episodes were defined on the basis of microbiological (positive cultures) or clinical documentation (signs and symptoms with positive CT scan or chest radiogram). When the body temperature exceeded 38°C, two blood and catheter cultures were drawn at least once daily. When a CVC infection was suspected, confirmation was obtained when receiving positive cultures from an infected insertion site, exit site, or pocket and catheter tip. In some cases, blood cultures were also collected two to three times after day 1 of the first febrile episode, with the hope of improving the number of bacteremias confirmed. Furthermore, a chest X-ray examination and, when necessary, computed tomography scan were carried out in febrile patients. Antibiotic therapy was started immediately after the temperature rose above 38°C. Table 2 illustrates initial antibiotic therapy employed. 
Statistical methods
Clinical charts were examined by the authors. Data were analyzed by descriptive statistical methods and differences between groups were calculated by using Fisher's exact test. Probability of events was obtained using the KaplanMeier method and groups were compared by the log-rank test. Factors affecting fever development were investigated using logistic multivariate analysis.
Results
Engraftment and mucositis
All patients became neutropenic after HDC. 
Incidence of febrile episodes and types of infections
Thirty-one cases (24%) experienced no fever, while the remaining 98 cases experienced at least one febrile episode (Table 2) . Eighty-three out of 98 cases (84.7%) developed fever during the period of severe neutropenia (Ͻ100 granulocytes/l), while only six episodes occurred with a neutrophil count above 500/l. The microbiologically and clinically documented infection rate was 45.9% (45/98 patients). Gram-positive pathogens -Staphylococcus epidermidis in 22 transplants -were the most frequent cause of microbiologically documented fevers, while in only five cases was infection due to a gram-negative organism (Escherichia coli in three cases, Pseudomonas aeroginosa in one case and Acinetobacter in another case). Fourteen patients had a CVC-related infection. Bacteremia was documented in 20 transplants.
Factors affecting fever development
Univariate analysis showed that, among variables analyzed, disease stages II-III, first PBSCT, mucositis grades II-IV and the use of two alkylating agents were associated with a higher risk of fever development (Table 3) . Of note, only one patient, amongst those who underwent two or three PBSCT, received two alkylators. Furthermore, a significantly higher number of cases of mucositis grades II-IV were documented in patients who received two alkylators (46 vs 21). Finally, duration of profound neutropenia (ANC Ͻ 100/l) did not depend on conditioning regimen (ie one vs two alkylators). On multivariate analysis, only grade of mucositis and number of alkylating agents were demonstrated to affect fever occurrence (Table 3) .
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Factors affecting probability of fever onset during neutropenia
Only 15% of patients developed fever before the 5th day whereas 50% of patients developed fever between the 7th and 8th day and the remaining 35% between the 9th and 12th day of neutropenia (Figure 1) . Median time to fever onset was significantly shorter in patients conditioned with double as compared to single alkylating agent-containing regimens (respectively 6th vs 8th day, P Ͻ 0.00001; Figure 2a ) and in patients with HRBC as compared with MBC (respectively 6th vs 8th day, P = 0.0002; Figure 2b ) and there was a trend for earlier onset in patients undergoing first PBSCT. Finally, mucositis grade did not influence time of fever onset. HRBC showed a 2.3-fold increased risk of developing early fever during neutropenia (CI 2.3-3.8) as compared with MBC, and thus remained the only variable still significant on multivariate analysis (P = 0.0039).
Response to antimicrobial therapy
Antibiotic therapy was administered for a median of 5 days and the antibiotic strategy used, either as single agent or in combination, was successful in controlling fever in all but 28 cases. It is interesting to note that combination therapy failed to demonstrate any significant additional advantage over single agent therapy, which was mainly cefitriaxone, both in terms of successful responses (62.7 vs 59.5%) and in terms of probability of fever duration. Of note, no variable was significantly associated with longer fever duration. However, patients with microbiologically documented fever were at higher risk of receiving second-line antibiotic therapy (Table 4) .
Discussion
HDC followed by stem cell rescue is now widely and increasingly used in patients with BC. [1] [2] [3] [4] [5] [6] However, the main disadvantage of this procedure is prolonged neutropenia, which is associated with fever and infectious complications, mainly when it is coupled with other additional risk factors, such as severe mucositis and interruption of natural barriers. 7, 8 Both waiting lists and cost containment pressures are becoming a major problem to keep in mind when managing a bone marrow transplant unit. Consequently, many centers have started to perform outpatient-based PBSCT using an inpatient-outpatient mixed care model, which produces substantial savings in costs without additional adverse effects in a selected group of patients with a standard risk of recurrent disease. 13 In this study, we retrospectively evaluated a cohort of BC patients treated with an inpatient approach, with the aim of identifying a patient population at low risk of developing fever and infection, suitable for a future outpatient transplant program. We considered fever and infectious complications in 90 BC patients, undergoing 129 transplants, homogeneously rescued with a relatively high number of PBSC, treated with antimicrobial prophylaxis and G-CSF post transplant and cared for in a positive-press- ure reverse isolation room during the neutropenic period. In this situation, the median duration of severe neutropenia was 5 days and р9 days in more than 90% of patients. About 3/4 of cases had at least one febrile episode and about 38% of them failed to respond to first-line antibiotic therapy. The risk of fever onset persisted up to the 11th day of neutropenia. These results are in line with previously reported data on infections in bone marrow transplant recipients. 16, 17 Multivariate analysis identified a group of patients conditioned with a single alkylating agent-containing regimen and with no or mild mucositis, that had a lower probability of developing fever. The number of alkylating agents did not influence the duration of profound neutropenia. However, the use of two alkylators is an independent risk factor for the development of fever and is also associated with a higher grade of mucositis. The latter, in turn, independently influences fever onset. Therefore, we were able to demonstrate that regimens containing two alkylators, although apparently not more myeloablative, increase the risk of fever development, probably through a mechanism of increased mucosal barrier disruption. A delay of fever onset was observed in about half of the cases, and, in particular, in those with metastatic disease or conditioned with a single alkylator-containing regimen. Unlike previous findings, 16 no significant variable analyzed in our study was associated with longer fever duration. This unexpected result is possibly due to the heterogeneous population of malignancies analyzed in the previous study 16 as compared to ours which includes only BC patients.
At this point, three major issues should be discussed. First, at comparable doses of chemotherapeutic agents, there is no proven superiority in terms of antineoplastic effects of a double alkylating as compared to a single alkylating agent regimen. Moreover, new therapeutic strategies that contain specific antineoplastic drugs are being proposed.
18-20 Consequently, we can feel free to use HDC with a single alkylating agent, such as melphalan or thiotepa, possibly associated with mitoxantrone or a novel agent.
Secondly, mucositis prophylaxis should be seriously considered for outpatient transplants. In this study, a previously described magnesium chloride containing solution 21 was used for all patients. However, new attempts should be considered to improve results. In this regard, administration of cytoprotectors, although expensive, might reduce the severity of HDC-related mucositis. 22, 23 Another critical issue might be fever management. In this retrospective study, both fever resolution and duration did not seem to be associated with the use of a single antibiotic or with any combination therapeutic approach. This may suggest the use of ceftriaxone prescribed once daily as a reasonable first-line therapeutic option to febrile, neutropenic, BC transplant patients receiving ambulatory management, although it must be confirmed in a prospective, randomized trial. Moreover, the sharp decrease in the incidence of bacteremia in the febrile neutropenic host 24 and the low outcome in terms of clinical information coming from stringent infection surveillance protocols have led physicians to limit blood cultures mainly to the first febrile episode, decreasing them by 49%. 25 In our study, a total of 588 blood cultures were performed (4.5/transplant) with an Bone Marrow Transplantation incidence of 6.3% of positivity, with no direct relationship between the number of blood cultures performed and the occurrence of bacteria isolation (data not shown). Of note, positive blood cultures obtained after 24 h from fever onset were confirmed to be the same pathogen in the follow-up cultures. The use of a single antimicrobial agent together with limited blood cultures should translate into savings in both costs and time for the outpatient setting.
In conclusion, these data support a rationale for a firststep approach of PBSCT for BC patients in the outpatient setting, and indicate single alkylator-containing regimens as the best choice for reducing risk of developing fever. Mucositis prophylaxis should be emphasized, regardless of costs. Finally, a single daily injection of ceftriaxone 26 for empirical treatment of first febrile episodes could be considered, although randomized prospective studies are needed.
